Patents Assigned to Amgen
  • Methods for refolding of recombinant antibodies
    Publication number: 20060194280
    Abstract: The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.
    Type: Application
    Filed: October 21, 2005
    Publication date: August 31, 2006
    Applicant: AMGEN INC.
    Inventors: Thomas Dillon, Douglas Rehder, Pavel Bondarenko, Margaret Ricci, Himanshu Gadgil, Douglas Banks, Joe Zhou, Yuefeng Lu
  • Osteoprotegerin binding proteins
    Patent number: 7097834
    Abstract: A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: August 29, 2006
    Assignee: Amgen Inc.
    Inventor: William J. Boyle
  • Cystine-knot polypeptides: Cloaked-2 molecules and uses thereof
    Publication number: 20060191027
    Abstract: The present invention relates to novel Cloaked-2 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing Cloaked-2 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with Cloaked-2 polypeptides.
    Type: Application
    Filed: January 6, 2006
    Publication date: August 24, 2006
    Applicant: AMGEN INC.
    Inventors: Christopher Paszty, Yongming Gao
  • Thrombopoietic compounds
    Publication number: 20060189531
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Application
    Filed: January 19, 2006
    Publication date: August 24, 2006
    Applicant: AMGEN INC.
    Inventors: Chuan-Fa Liu, Ulrich Feige, Janet Cheetham
  • IL-17 receptor like molecules and uses thereof
    Patent number: 7094566
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 22, 2006
    Assignee: Amgen Inc.,
    Inventors: Eugene Medlock, Richard Yeh, Scott M. Silbiger, Gary S. Elliott, Hung Q. Nguyen, Shuqian Jing
  • N-terminally chemically modified protein compositions and methods
    Patent number: 7090835
    Abstract: Provided herein are methods and compositions relating to the attachment of water soluble polymers to proteins. Provided are novel methods for N-terminally modifying proteins or analogs thereof, and resultant compositions, including novel N-terminally chemically modified G-CSF compositions and related methods of preparation. Also provided is chemically modified consensus interferon.
    Type: Grant
    Filed: March 26, 2001
    Date of Patent: August 15, 2006
    Assignee: Amgen, Inc.
    Inventors: Nancy E. Gabriel, Christine E. Farrar
  • Method of treating anemia by administering IL-1ra
    Patent number: 7087224
    Abstract: The invention relates to methods of treating a blood disorder in a mammal with an interleukin-1 (IL-1) inhibitor. The invention also relates to methods of treating a blood disorder in a mammal with an IL-1 inhibitor, a TNF inhibitor and an erythropoietin (EPO) receptor agonist. The invention also relates to compositions of an IL-1 inhibitor and compositions of an IL-1 inhibitor, a TNF inhibitor and an EPO receptor agonist.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: August 8, 2006
    Assignee: Amgen Inc.
    Inventors: Jonathan Kay, Dorothy McCabe, Richard Newmark, Marco A. Coccia
  • Compositions and methods of treating fibrotic disorders
    Publication number: 20060171943
    Abstract: The invention provides methods and compositions for reducing or preventing fibrosis in a subject suffering from a fibrotic disorder by administering a therapeutically effective amount of at least one antagonist to the cytokine thymic stromal lymphopoietin to the subject. In one embodiment, the methods and compositions further comprise administering at least one additional antagonist to an additional profibrotic cytokine, growth factor or chemokine.
    Type: Application
    Filed: January 31, 2006
    Publication date: August 3, 2006
    Applicant: Amgen Inc.
    Inventors: Michael Comeau, David Fitzpatrick
  • G-protein coupled receptors
    Patent number: 7084259
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of four novel G-protein coupled receptors that are amplified in breast cancer cells, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of G-protein coupled receptors.
    Type: Grant
    Filed: August 4, 2003
    Date of Patent: August 1, 2006
    Assignee: Amgen Inc.
    Inventors: Scott Powers, Jianxin Yang, Gene Cutler
  • Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
    Patent number: 7084257
    Abstract: Selective binding agents of interferon-gamma (IFN?) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to IFN? and may be used to prevent or treat conditions relating to autoimmune and inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and multiple sclerosis. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: August 1, 2006
    Assignee: Amgen Inc.
    Inventors: Rajendra V. Deshpande, Mei-Mei Tsai
  • Antibodies which activate an erythropoietin receptor
    Patent number: 7081523
    Abstract: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: July 25, 2006
    Assignee: Amgen Inc.
    Inventor: Steven Elliott
  • Fibroblast Growth Factor-23 molecules and uses thereof
    Publication number: 20060160181
    Abstract: The present invention provides Fibroblast Growth Factor-23 (FGF-23) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGF-23 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGF-23 polypeptides.
    Type: Application
    Filed: September 28, 2005
    Publication date: July 20, 2006
    Applicant: Amgen Inc.
    Inventors: Roland Luethy, Robert Yang, Sidney Suggs, Iidiko Sarosi
  • Substituted heterocyclic compounds and methods of use
    Publication number: 20060161001
    Abstract: The present invention relates to nitrogen-containing bicyclic structures and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic ? cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs.
    Type: Application
    Filed: December 19, 2005
    Publication date: July 20, 2006
    Applicant: Amgen Inc.
    Inventors: Fang-Tsao Hong, Hongyu Liao, Patricia Lopez, Seifu Tadesse, Nuria Tamayo
  • Selective binding agents of telomerase
    Patent number: 7078491
    Abstract: The present invention relates to novel selective binding agents including polyclonal and monoclonal antibodies that recognize and bind to the catalytic subunit of human telomerase (hTERT). The invention also relates to the production, diagnostic use, and therapeutic use of the hTERT antibodies and fragments thereof.
    Type: Grant
    Filed: September 20, 2001
    Date of Patent: July 18, 2006
    Assignee: Amgen Inc.
    Inventor: Lea A. Harrington
  • Kinase inhibitors
    Patent number: 7074789
    Abstract: The invention relates to inhibitors of enzymes that bind to ATP or GTP and/or catalyze phosphoryl transfer, compositions comprising the inhibitors, and methods of using the inhibitors and inhibitor compositions. The inhibitors and compositions comprising them are useful for treating disease or disease symptoms. The invention also provides for methods of making phosphoryl transferase inhibitor compounds, methods of inhibiting phosphoryl transferase activity, and methods for treating disease or disease symptoms.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: July 11, 2006
    Assignee: Amgen Inc.
    Inventors: David M. Armistead, Jean E. Bemis, John L. Buchanan, Lucian V. DiPietro, Daniel Elbaum, Stephanie D. Geuns-Meyer, Gregory J. Habgood, Joseph L. Kim, Teresa L. Marshall, Perry M. Novak, Joseph J. Nunes, Vinod F. Patel, Leticia M. Toledo-Sherman, Xiaotian Zhu
  • Arylsulfonamidobenzylic compounds
    Patent number: 7071358
    Abstract: Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: July 4, 2006
    Assignee: Amgen Inc.
    Inventors: Xian Yun Jiao, Frank Kayser, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
  • Tissue inhibitor of metalloproteinase type three (TIMP-3) composition and methods
    Patent number: 7071317
    Abstract: The present invention relates in general to metalloproteinase inhibitors and to polynucleotides encoding such inhibitors. In particular, the invention relates to novel mammalian inhibitors of metalloproteinase, which are designated as type three or TIMP-3, to fragments, derivatives, and analogs thereof, and to polynucleotides encoding the same. Novel methods of producing such compositions and novel methods of using such compositions are also provided.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: July 4, 2006
    Assignee: Amgen Inc.
    Inventors: Scott M. Silbiger, Raymond A. Koski
  • CXCR3 antagonists
    Patent number: 7067662
    Abstract: Compounds, compositions and methods that are useful in the treatment of inflammatory and immune conditions and diseases are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of a chemokine receptor. The subject methods are useful for the treatment of inflammatory and immunoregulatory disorders and diseases, such as multiple sclerosis, rheumatoid arthritis and type I diabetes.
    Type: Grant
    Filed: September 21, 2004
    Date of Patent: June 27, 2006
    Assignee: Amgen SF, LLC
    Inventors: Julio C. Medina, Michael G. Johnson, An-Rong Li, Jiwen Liu, Alan Xi Huang, Liusheng Zhu, Andrew P. Marcus
  • Antibodies to Dkk-1
    Publication number: 20060127393
    Abstract: The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 protein. Methods for preparing such antibodies or fragments thereof as well as physiologically acceptable compositions containing the antibodies or fragments are also provided. Use of the antibodies and fragments to treat various diseases including bone disorders, inflammatory diseases, neurological diseases, ocular diseases, renal diseases, pulmonary diseases and skin diseases are also disclosed.
    Type: Application
    Filed: August 4, 2005
    Publication date: June 15, 2006
    Applicant: Amgen Inc.
    Inventors: Ji Li, Wenyan Shen, Hsieng Lu, William Richards
  • Arylsulfonanilide ureas
    Patent number: 7060718
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: June 13, 2006
    Assignee: Amgen Inc.
    Inventor: Jonathan B. Houze